Polymorphonuclear blood leukocytes and restenosis after intracoronary implantation of drug-eluting stents.
Peripheral blood contents of osteonectin-positive progenitor cells and polymorphonuclear granulocytes were examined by flow cytometry in 38 patients after myocardial revascularisation with drug-eluting stents. Repeat coronary angiography performed 6-12 months after stent implantation revealed in-stent restenosis in 15 patients and its absence in 23 patients. The plasma levels of osteonectin-positive progenitor cells, neutrophils, and basophils did not differ in patients with and without restenosis. Eosinophil blood levels in patients with and without restenosis were 262+/-68 and 124+/-67 cells/microL (mean+/-SD, p<0.001), respectively. Only one of 19 patients (5%) with eosinophil content lower than the distribution median for the entire group developed restenosis, whereas in the group with eosinophil contents higher than the median (n=19) restenosis occurred in 14 patients (74%, p<0.001). Our findings suggest that the frequency of restenoses after stenting is related to high peripheral blood eosinophil content.
Gabbasov
Zufar A
ZA
Laboratory of Stem Cells and Department of Atherosclerosis, Institute of Experimental Cardiology, Cardiology Research Center, 3rd Cherepkovskaya Street, 15A, Moscow 121 552, Russia. gabbasov@cardio.ru
Kozlov
Sergey G
SG
Lyakishev
Anatoly A
AA
Saburova
Olga S
OS
Smirnov
Vladimir A
VA
Smirnov
Vladimir N
VN
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000295:instrumentation; D016022:Case-Control Studies; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*; D054855:Drug-Eluting Stents; D004802:Eosinophilia / Q000097:blood / Q000209:etiology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism*; D015676:Osteonectin / Q000097:blood*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D015676:Osteonectin; D010975:Platelet Aggregation Inhibitors